Phase1/‐2 study of Pomalidomide in myelofibrosis
Ruben A. Mesa(Atrium Health Wake Forest Baptist), Ayalew Tefferi(Mayo Clinic), Susan M. Schwager(Mayo Clinic in Arizona), William J. Hogan(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Wenting Wu(East China Normal University), Kebede Hussein(Mayo Clinic), Animesh Pardanani(Mayo Clinic)
Cited by 87
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k